TMCnet News
Erasca Strengthens Leadership Team with Two Key Executive AppointmentsLisa Tesvich-Bonora appointed as Chief People Officer Robert Shoemaker promoted to Senior Vice President of Research SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Lisa Tesvich-Bonora as Chief People Officer and the promotion of Robert Shoemaker to Senior Vice President of Research. “I am thrilled to welcome Lisa to the Erasca family. With over two decades of experience in creating collaborative and engaging environments where employees can thrive, she brings a wealth of strategic leadership expertise in organizational development and talent management,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Lisa will help architect and implement Erasca’s people-centric initiatives, including recruitment, training, and professional development. We look forward to Lisa taking the lead in advancing our culture and talent initiatives at Erasca, reinforcing our core values and cultivating the development of our most important asset: our people.” Dr. Lim continued, “I am also very pleased to announce Robert’s promotion to Senior Vice President of Research. Robert was a core member of Erasca’s founding, has been instrumental in elevating the quality and visibility of Erasca’s science, helped Erasca raise $665 million in financing, and is well-respected across both internal and external stakeholders. We are excited to promote Robert to lead the integration of Discovery Research activities across Biology, Chemistry, and DMPK to drive successful advancement of Erasca’s product candidates from Research to Development.” About Lisa Tesvich-Bonora, Ph.D. Dr. Tesvich-Bonora brings more than 20 years of experience as a strategic leadership consultant, with expertise in organizational development, culture, and talent management. She has partnered with diverse leaders and teams in the life sciences industries of biotechnology, pharmaceuticals, and contract research organizations as well as across a multitude of other industries including hospitals, technology, energy, financial services, telecommunications, and law enforcement, and she has served as a volunteer coach to former U.S. Navy SEALs. Prior to joining Erasca, she was founder and president of Inspire True Leadership, an organizational advisory company focused on enabling business growth through leadership excellence and a strong people genda. She also was a director at Mellon Financial and a director in the global human resources practice of PricewaterhouseCoopers. Dr. Tesvich-Bonora holds Ph.D. and M.S. degrees in industrial/organizational psychology from Tulane University and a B.A. in psychology from the University of California, Santa Barbara. About Robert Shoemaker, Ph.D. Dr. Shoemaker has served as Erasca’s Vice President of Biology since helping launch the company in July 2018. Bringing over 20 years of experience and education in computational biology, he has deep biology, bioinformatics, and drug development experience. Prior to Erasca, Dr. Shoemaker led the computational biology group at Ignyta, where he worked since the company’s inception in 2011 until its acquisition by Roche in 2018. He contributed to the successful development of lead drug candidate entrectinib by developing a patient selection strategy. He also led biomarker development for other preclinical and clinical candidates and developed a novel prototype blood-based next generation sequencing (NGS) assay for detecting autoimmune diseases. Before working at Ignyta, he was a scientist at Illumina, where he helped develop new products and investigate product quality via NGS data analysis. Dr. Shoemaker earned his Ph.D. in biochemistry at the University of California, San Diego. About Erasca Cautionary Note Regarding Forward-Looking Statements Contact: Source: Erasca, Inc. |